Shiffman Mitchell L
Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA.
Liver Int. 2016 Jan;36 Suppl 1:62-6. doi: 10.1111/liv.13012.
Chronic hepatitis C virus (HCV) infection affects an estimated 123 million persons worldwide and is the leading cause of cirrhosis and hepatocellular carcinoma in most countries. Approximately 75% of persons with chronic HCV were born between the years 1945-1965 and screening of patients in this birth cohort is now advocated. Unfortunately, these recommendations are not readily applied and a sizable population of infected persons who could benefit from treatment fall outside the birth cohort. Universal screening for HCV would be optimal. However, the primary limitation once patients are identified is accessing treatment which remains restricted in most countries.
慢性丙型肝炎病毒（HCV）感染估计影响全球1.23亿人，是大多数国家肝硬化和肝细胞癌的主要病因。约75%的慢性HCV感染者出生于1945年至1965年之间，目前提倡对这一出生队列中的患者进行筛查。不幸的是，这些建议并未得到广泛应用，大量可从治疗中获益的感染者不在该出生队列范围内。对HCV进行普遍筛查是最佳选择。然而，一旦确定患者，主要限制在于获得治疗，而在大多数国家，治疗仍然受限。
